Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Omigapil> ?p ?o. }
Showing items 1 to 46 of
46
with 100 items per page.
- Omigapil abstract "Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD).Omigapil was first synthesized at Ciba-Geigy, Basel, Switzerland. Santhera Pharmaceuticals has since taken over production of omigapil and preclinical trials for CMD. In May 2008, omigapil was granted orphan designation to commence clinical trials for. Pharmacokinetic trials are scheduled to commence enrollment in the second half of 2012 to determine the appropriate pharmacokinetic profile of the drug for children with laminin-α2-deficient congenital muscular dystrophy (MDC1A) and collagen VI related myopathy. Santhera Pharmaceuticals will use the phase 1 clinical trial to determine if the drug is safe and acts with the same pharmacokinetic profile in children as it does in adults. The impending clinical trial will take place in the United States at the National Institute of Neurological Disorders and Stroke/National Institute of Health(NNDCS/NINDS) (Bethesda, Maryland) and in the United Kingdom at Great Ormond Street Hospital (UCL).".
- Omigapil atcPrefix "None".
- Omigapil casNumber "181296-84-4".
- Omigapil fdaUniiCode "5V14HD0N4Q".
- Omigapil iupacName "Dibenzo[b,f]oxepin-10-ylmethyl-methyl-prop-2-ynylamine".
- Omigapil pubchem "6419718".
- Omigapil thumbnail Omigapil_skeletal.svg?width=300.
- Omigapil wikiPageExternalLink index.php.
- Omigapil wikiPageID "3139976".
- Omigapil wikiPageRevisionID "592701085".
- Omigapil atcPrefix "None".
- Omigapil c "19".
- Omigapil casNumber "181296".
- Omigapil h "17".
- Omigapil hasPhotoCollection Omigapil.
- Omigapil iupacName "Dibenzo[b,f]oxepin-10-ylmethyl-methyl-prop-2-ynylamine".
- Omigapil legalStatus "Investigational".
- Omigapil molecularWeight "275.13".
- Omigapil n "1".
- Omigapil o "1".
- Omigapil pubchem "6419718".
- Omigapil smiles "C=3c1ccccc1Oc2ccccc2C=3CNCC#C".
- Omigapil stdinchi "1".
- Omigapil stdinchikey "QLMMOGWZCFQAPU-UHFFFAOYSA-N".
- Omigapil synonyms "TCH346, CGP3466B".
- Omigapil unii "5".
- Omigapil subject Category:Drugs_acting_on_the_nervous_system.
- Omigapil subject Category:Orphan_drugs.
- Omigapil type Agent114778436.
- Omigapil type CausalAgent100007347.
- Omigapil type Drug103247620.
- Omigapil type DrugsActingOnTheNervousSystem.
- Omigapil type Matter100020827.
- Omigapil type PhysicalEntity100001930.
- Omigapil type Substance100020090.
- Omigapil type Drug.
- Omigapil type FunctionalSubstance.
- Omigapil comment "Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD).Omigapil was first synthesized at Ciba-Geigy, Basel, Switzerland.".
- Omigapil label "Omigapil".
- Omigapil sameAs m.08tzg6.
- Omigapil sameAs Q7090184.
- Omigapil sameAs Q7090184.
- Omigapil sameAs Omigapil.
- Omigapil wasDerivedFrom Omigapil?oldid=592701085.
- Omigapil depiction Omigapil_skeletal.svg.
- Omigapil isPrimaryTopicOf Omigapil.